KIORA PHARMACEUTICALS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
KIORA PHARMACEUTICALS, INC. (KPRX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $2.91 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-07
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $0.93.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2022-03-31 was $2.79, a 58.85% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $7.04, a 84.91% decline from fiscal 2023.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $46.64, a 89.55% decline from fiscal 2022.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $446.34, a 71.87% increase from fiscal 2021.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2021 was $259.70, a 3506.94% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $2.91 10-Q · filed 2026-08-07 | ||||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-09 | ||||
| 2024-12-31 | $7.04 10-K · filed 2026-03-25 | ||||
| 2024-09-30 | $7.04 10-Q · filed 2024-11-08 | ||||
| 2024-06-30 | $8.37 10-Q · filed 2024-08-09 | ||||
| 2024-03-31 | $0.93 10-Q · filed 2024-05-10 | ||||
| 2023-12-31 | $46.64 10-K · filed 2025-03-25 | $5.08 10-K · filed 2024-03-25 | |||
| 2023-09-30 | $6.05 10-Q · filed 2023-11-09 | ||||
| 2023-06-30 | $7.93 10-Q · filed 2023-08-08 | ||||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | ||||
| 2022-12-31 | $446.34 10-K · filed 2024-03-25 | ||||
| 2022-06-30 | $2.65 10-Q · filed 2022-08-12 | ||||
| 2022-03-31 | $2.79 10-Q · filed 2022-07-08 | ||||
| 2021-12-31 | $259.70 10-K · filed 2023-03-23 | $6.49 10-K · filed 2022-04-15 | |||
| 2021-09-30 | $6.51 10-Q · filed 2021-11-15 | ||||
| 2021-06-30 | $6.51 10-Q · filed 2022-08-12 | ||||
| 2021-03-31 | $6.78 10-Q · filed 2021-05-12 | ||||
| 2020-12-31 | $7.20 10-K/A · filed 2022-07-07 | ||||
| 2020-09-30 | $7.20 10-Q · filed 2021-11-15 | ||||
| 2020-06-30 | $7.20 10-Q · filed 2021-08-12 | $7.20 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $7.20 10-Q · filed 2021-05-12 | ||||
| 2019-12-31 | $9.19 10-K · filed 2021-03-25 | ||||
| 2019-09-30 | $9.19 10-Q · filed 2020-11-09 | ||||
| 2018-12-31 | $15.44 10-K · filed 2020-03-04 | ||||
| 2018-09-30 | $15.95 10-Q · filed 2019-11-07 | ||||
| 2018-06-30 | $0.83 10-Q · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |